Role of peroxynitrite in methamphetamine-induced dopaminergic neurodegeneration and neuroprotection by antioxidants and selective NOS inhibitors.
Ali
Syed F
SF
Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research/FDA, Jefferson, Arkansas 72079, USA. sali@nctr.fda.gov
Imam
Syed Z
SZ
Itzhak
Yossef
Y
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D018765:Dopamine Uptake Inhibitors / Q000633:toxicity*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D007191:Indazoles / Q000494:pharmacology / Q000627:therapeutic use; D008694:Methamphetamine / Q000633:toxicity*; D051379:Mice; D018345:Mice, Knockout; D019636:Neurodegenerative Diseases / Q000473:pathology* / Q000517:prevention & control*; D018696:Neuroprotective Agents; D020030:Nitric Oxide Donors / Q000494:pharmacology / Q000627:therapeutic use; D052248:Nitric Oxide Synthase Type I / Q000037:antagonists & inhibitors* / Q000235:genetics; D030421:Peroxynitrous Acid / Q000378:metabolism*
D000975:Antioxidants; D018765:Dopamine Uptake Inhibitors; D004791:Enzyme Inhibitors; D007191:Indazoles; D018696:Neuroprotective Agents; D020030:Nitric Oxide Donors; D030421:Peroxynitrous Acid; D008694:Methamphetamine; D052248:Nitric Oxide Synthase Type I; C080122:7-nitroindazole